GPI-80 Defines Self-Renewal Ability in Hematopoietic Stem Cells during Human Development  by Prashad, Sacha Leandra et al.
Short ArticleGPI-80 Defines Self-Renewal Ability in
Hematopoietic Stem Cells during Human
DevelopmentGraphical AbstractHighlightsd Human fetal HSCs with self-renewal ability express GPI-80, a
myeloid adhesion factor
d The migration of HSPCs between fetal hematopoietic sites
can be tracked by GPI-80
d GPI-80 expression distinguishes HSPCs that have emerged
from endothelium
d GPI-80 and ITGAM colocalize on the cell surface to facilitate
HSC self-renewalPrashad et al., 2015, Cell Stem Cell 16, 80–87
January 8, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.stem.2014.10.020Authors
Sacha Leandra Prashad,
Vincenzo Calvanese, ...,
Mattias Magnusson, Hanna Katri
Annikki Mikkola
Correspondence
hmikkola@mcdb.ucla.edu
In Brief
In leukocytes, the cell surface marker
GPI-80 cooperates with ITGAM to
support adhesion andmigration. Prashad
et al. here report that GPI-80 identified
functional fetal human hematopoietic
stem cells (HSCs). Coexpression of GPI-
80 and ITGAM was necessary for HSC
in vitro expansion and engraftment,
illustrating how fetal HSCs repurpose a
mechanism to mediate self-renewal.
Cell Stem Cell
Short ArticleGPI-80 Defines Self-Renewal Ability
in Hematopoietic Stem Cells
during Human Development
Sacha Leandra Prashad,1,2,3 Vincenzo Calvanese,1,2 Catherine Yao Yao,1,2 Joshua Kaiser,1,2 Yanling Wang,1
Rajkumar Sasidharan,1,2 Gay Crooks,1,2,4,5 Mattias Magnusson,1,2 and Hanna Katri Annikki Mikkola1,2,3,5,*
1Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA
2Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles,
CA 90095, USA
3Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
4Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
5Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA
*Correspondence: hmikkola@mcdb.ucla.edu
http://dx.doi.org/10.1016/j.stem.2014.10.020SUMMARY
Advances in pluripotent stem cell and reprogram-
ming technologies have given us the hope of gener-
ating hematopoietic stem cells (HSCs) in culture.
To succeed, greater understanding of the self-re-
newing HSC during human development is required.
We discovered that the glycophosphatidylinositol-
anchored surface protein GPI-80 defines a sub-
population of human fetal liver hematopoietic stem/
progenitor cells (HSPCs) with self-renewal ability.
CD34+CD38lo/CD90+GPI-80+ HSPCs were the sole
population that maintained proliferative potential
and an undifferentiated state in stroma coculture
and engrafted in immunodeficient mice. GPI-80
expression also enabled tracking of HSPCs once
they emerged from endothelium and migrated be-
tween human fetal hematopoietic niches. GPI-80 co-
localized on the surface of HSPCs with Integrin
alpha-M (ITGAM), which in leukocytes cooperates
with GPI-80 to support migration. Knockdown of
GPI-80 or ITGAM was sufficient to compromise
HSPC expansion in culture and engraftment in vivo.
These findings indicate that human fetal HSCs
employ mechanisms used in leukocyte adhesion
and migration to mediate HSC self-renewal.
INTRODUCTION
The ability to replenish blood and immune cells relies on rare he-
matopoietic stem cells (HSCs) that can differentiate into all blood
cell types, self-renew, and engraft upon transplantation (Morri-
son et al., 1995a; Weissman, 2000). HSCs hold immense thera-
peutic value for treating hematological disorders (Bordignon,
2006; Shenoy, 2013); however, there is a shortage of immuno-
compatible HSC donors, particularly for patients of minority
descent or mixed ethnic background (Dehn et al., 2008). Use80 Cell Stem Cell 16, 80–87, January 8, 2015 ª2015 Elsevier Inc.of induced pluripotent stem cells (iPSCs) or lineage reprogram-
ming strategies provide a promising avenue for the generation
of patient-specific HSCs (Dravid and Crooks, 2011; Risuen˜o
et al., 2012). However, better understanding of HSC emergence
and expansion during human development is critical for identi-
fying programs necessary for the in vitro generation and mainte-
nance of HSCs that fulfill the functional and safety criteria for
transplantation to patients.
The first hematopoietic cells in the embryo emerge in the yolk
sac and first generate a cohort of primitive erythroblasts, after
which come erythro-myeloid progenitors that initiate fetal liver
(FL) erythropoiesis (Mikkola and Orkin, 2006). Subsequently,
HSCs emerge in the dorsal aorta, vitelline and umbilical arteries,
the yolk sac, and the placenta from specialized, ‘‘hemogenic’’
endothelium (Chen et al., 2009; Rhodes et al., 2008; Zovein
et al., 2008). HSCs then seed the FL for expansion, after which
they migrate to their lifelong niche in the bone marrow (BM)
where they become predominantly quiescent (Ciriza et al.,
2013). Although the sites for HSC emergence and expansion
were first established in mice, the same anatomical sites have
been shown to support hematopoiesis during human develop-
ment (Van Handel et al., 2010; Ivanovs et al., 2011; Robin
et al., 2009; Tavian et al., 2010).
Insufficient knowledge of the surface proteins specific to hu-
man HSCs has hampered studies of their regulation. Many
well-established murine HSC markers such as Sca1 and the
SLAM markers are not conserved in human (Larochelle et al.,
2011). Moreover, HSC surface markers change during develop-
ment as shown in mouse embryos (McKinney-Freeman et al.,
2012; Mikkola and Orkin, 2006). Previous studies suggest that
human longterm repopulating HSCs reside in the CD34+
CD38lo/CD90+ population in both cord blood (CB) and fetal
hematopoietic tissues (Hogan et al., 2002; Magnusson et al.,
2013; Majeti et al., 2007; McKenzie et al., 2007). However,
because both endothelium and HSCs coexpress CD34 and
CD90, thesemarkers do not distinguish HSCs from endothelium.
Thus, markers that demarcate human HSCs from short-lived
progenitors or endothelium remain elusive.
Here we define glycosylphosphatidylinositol-anchored sur-
face protein (GPI-80; also known as Vanin-2, or VNN2) as a
Figure 1. A Subpopulation of Human FL
HSPCs Express GPI-80/VNN2
(A) Flow cytometry plot of hematopoietic pop-
ulations from Ficoll-purified week 15 human FL
with CD34, CD38, and CD90 documenting
subfractionation of CD34+ cells to P1 (CD34+
CD38lo/CD90+), P2 (CD34+CD38lo/CD90), and
P3 (CD34+CD38+CD90). Quadrants were drawn
according to fluorescence minus one (FMO)
control.
(B) Quantification of engrafted cells in murine BM
at 16 weeks posttransplantation with representa-
tive flow cytometry plots (n = 3 mice/group).
(C) Quantile-Quantile plots comparing differ-
entially expressed genes between P1 (CD34+
CD38lo/CD90+) and P2 (CD34+CD38lo/CD90)
or P3 (CD34+CD38+CD90).
(D) Twenty cell surface proteins upregulated
in CD34+CD38lo/CD90+ HSPCs versus CD34+
CD38lo/CD90 HPCs.
(E) qRT-PCR of GPI-80 mRNA in the CD34+
CD38lo/CD90+ population as compared to
CD34+CD38lo/CD90 and CD34+CD38+CD90
cells (p% 0.01) (n = 3 different donor tissues). Error
bars represent mean ± SEM.
(F) Representative flow cytometry plot of Ficoll-
purified, CD34+ enriched cells from 15 week
developmental age FL stained for CD34, CD38,
CD90, and GPI-80. FMO control for GPI-80 is
shown. See also Figure S1 and Table S1.
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GPI-80 Marks Human Fetal HSCssurface marker for HSCs during human development by func-
tionally validating surface proteins highly enriched in undifferen-
tiated FL HSPCs. We discovered that GPI-80 distinguishes a
population of self-renewing HSCs and allows tracking HSCs in
multiple developmental niches. Molecular analysis of GPI-80
HSPCs provides new insight into the regulatory machinery in
the highly self-renewing fetal HSCs and reveals that fetal HSCs
preserve self-renewal ability using mechanisms utilized in leuko-
cyte adhesion and migration.
RESULTS
GPI-80 Expression Defines a Subpopulation of Human
FL HSPCs
Our goal was to define the identity andmolecular properties of FL
HSCs, which are highly self-renewing, and the most potent hu-
man HSC when they were transplanted to immunodeficientCell Stem Cell 16, 80–mice (Holyoake et al., 1999). FL HSCs
are ontologically closer to PSC-derived
hematopoietic cells than adult BM or
CB, thereby representing an ideal model
to study human HSC self-renewal and
the molecular blocks hampering in vitro
HSC generation. To identify candidate
surfacemarkers for the highly self-renew-
ing fetal HSC, we performed gene
expression analysis on HSPC subsets
isolated from second trimester (week
15–18 of developmental age) human FL.
An HSC enriched population and theirdownstream progeny were isolated from Ficoll-purified, CD34-
enriched FL cells using previously established HSPC surface
markers: CD34+CD38lo/CD90+ (P1, most undifferentiated),
CD34+CD38lo/CD90 (P2), and CD34+CD38+CD90 (P3)
(Figure 1A). As expected, 16 weeks after transplantation into
NOD-scid IL2Rg-null (NSG) mice, robust BM engraftment was
detected only in mice transplanted with P1 cells (Figure 1B).
These data verified that FL HSC engraftment ability is restricted
to the CD34+CD38lo/CD90+ (P1) population, henceforth
referred to as HSPCs, while P2 and P3 consist of hematopoietic
progenitor cells (HPCs).
To generate candidates for further purification of HSCs, we
used Affymetrix microarray analysis to identify surface proteins
enriched in CD34+CD38lo/CD90+ HSPCs as compared to
downstream HPCs. A total of 1,274 genes were upregulated
>2-fold and 1,369 genes were >2-fold downregulated in P1
HSPCs as compared to P2 HPCs (p < 0.05). Quantile-Quantile87, January 8, 2015 ª2015 Elsevier Inc. 81
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GPI-80 Marks Human Fetal HSCs(Q-Q) analysis of differentially expressed genes confirmed that
the P1 population was more similar to P2 than it was to P3 (Fig-
ure 1C). Candidate HSC surface proteins were selected from the
most highly upregulated membrane proteins on P1 HSPCs (Fig-
ure 1D, Table S1 available online). Of these, Endomucin (EMCN)
and Endothelial Protein C Receptor (PROCR, also known as
EPCR) have been previously identified as markers that enrich
for HSCs (Balazs et al., 2006; Matsubara et al., 2005).
GPI-80 (Figure 1D), a molecule that governs neutrophil adhe-
sion and transendothelial migration (Suzuki et al., 1999),
was 16.7-fold upregulated in P1 HSPCs. Upregulation of GPI-
80 mRNA in P1 HSPCs as compared to downstream HPCs
(P2 and P3) was verified by qRT-PCR (Figure 1E). Flow cytom-
etry analysis indicated that GPI-80 surface expression sub-
fractionated FL HSPCs into a distinct GPI-80+ subpopulation
(32% ± 7.0% of P1) (Figure 1F). Minimal GPI-80 surface
expression was found in CD34+CD38lo/CD90 (P2) or CD34+
CD38+CD90 (P3) HPCs, confirming that its expression within
the Ficoll-purified FL CD34+ compartment was restricted to
the most undifferentiated HSPCs. However, some expression
was detected in more differentiated CD34 cells (Figure S1A
available online). The expected expression of GPI-80 in myeloid
cells in FL and adult peripheral blood was confirmed by flow
cytometry (Figure S1B). Markers associated with HSPC differ-
entiation such as CD45RA (Figure S1C), or the myelo-erythoid
lineage markers CD14, CD66, CD13, and CD235, were not
coexpressed with GPI-80 HSPCs and therefore would not
further purify this subset in Ficoll-purified, CD34-enriched FL;
however, if total FL was analyzed, cells coexpressing myeloid
markers were found within the GPI-80+ HSPC population
(Figure S1D). The percentage of CD45 cells that have the
GPI-80+CD34+CD38lo/CD90+ phenotype in total FL ranged
from 0.03% to ±0.01%; however, over 60% of these cells co-
express at least one myeloid marker. In the Ficoll-purified,
CD34-enriched fraction, the frequency of GPI-80+ HSPCs
was 1.4% ± 1.2%. To ensure maximum purity of HSPCs, Fi-
coll-purified FL was used for all the assays unless otherwise
noted. These data implied that, in addition to having a function
in the myeloid compartment, GPI-80 is also expressed in undif-
ferentiated human fetal HSPCs.
GPI-80+ HSPCs Exhibit Robust Multilineage
Differentiation Potential
GPI-80+ and GPI-80 fractions of FL HSPCs were FACS sorted
and evaluated for key HSC properties: multipotency, self-
renewal, and engraftment ability. Both HSPC fractions gener-
ated myeloid and erythroid colonies, although GPI-80+ HSPCs
formed fewer colonies than GPI-80 cells (Figure S2A). When
B- and T-lymphoid differentiation potential was assayed on
OP9M2 (Magnusson et al., 2013; Nakano et al., 1994) and
OP9DL1 stroma (Schmitt and Zu´n˜iga-Pflu¨cker, 2002), respec-
tively, as bulk cultures, both GPI-80+ and GPI-80 cells formed
CD19+ B cells (Figure S2B) and CD4/CD8+ T cells (Figure S2C).
To investigate multilineage differentiation ability at the clonal
level, GPI-80+ and GPI-80 HSPCs were sorted as single cells
and cultured on OP9M2 in conditions that support both myeloid
and B cell differentiation. After 2 weeks, expanded clones
were enumerated and scored as myeloid (CD13+, CD14+, or
CD66+ cells), lymphoid (CD19+ cells), myelo-lymphoid, or82 Cell Stem Cell 16, 80–87, January 8, 2015 ª2015 Elsevier Inc.undifferentiated (>30% CD34+ cells with minimal expression
of differentiation markers). Clones were scored as prolifer-
ative if >200 daughter cells after 14 days were observed.
GPI-80+ HSPCs averaged 33% proliferating clones whereas
GPI-80 HSPCs averaged 25% (Figure S2D). Furthermore,
GPI-80+ HSPCs demonstrated enrichment in clones that re-
mained largely undifferentiated or displayed myelo-lymphoid
differentiation, whereas GPI-80 HSPC clones gave rise pre-
dominantly to myeloid progeny. These data imply that, although
both GPI-80+ and GPI-80 HSPCs possess multilineage differ-
entiation ability in bulk culture, only GPI-80+ HSPCs display
robust multipotency at the clonal level.
In Vitro Expansion Ability Is Restricted to GPI-80+ HSPCs
We next evaluated in vitro self-renewal ability of GPI-80+ and
GPI-80 HSPCs on OP9M2 stroma; we have previously shown
that this mesenchymal stem cell (MSC)-like stroma line sup-
ports robust expansion of human FL HSPCs over several
weeks and maintains transplantable HSCs for over 2 weeks
in culture (Magnusson et al., 2013). After 2 and 4 weeks, the dif-
ferentiation status of GPI-80+ and GPI-80 HSPCs was as-
sessed by cell surface phenotype. Strikingly, only GPI-80+
HSPCs showed robust expansion of HSPCs (>1,000-fold in
4 weeks), a subpopulation of which continued to express
GPI-80 (Figure 2A). In contrast, GPI-80 cells were unable to
maintain HSPCs in culture and exhibited limited proliferative
potential. These data indicate that the GPI-80+ subpopulation
is fully responsible for the in vitro expansion of undifferentiated
CD34+CD38lo/CD90+ HSPCs.
Cell cycle analysis using BrdU incorporation in HSPCs in
OP9M2 coculture (Figure 2B) revealed that both GPI-80+ and
GPI-80 HSPCs show similar distribution between cell cycle
phases, while CD34+CD38lo/CD90 cells exhibit a reduction of
S-phase cells. These data suggest that the poor expansion of
GPI-80 HSPCs in culture is not due to lower proliferation rate,
but rather due to the inability of GPI-80 HSPCs to undergo self-
renewal divisions to maintain/expand undifferentiated HSPCs.
GPI-80 Identifies In Vivo Engraftable Fetal HSCs
To assess the in vivo engraftment and reconstitution ability of
GPI-80+ HSPCs, xenotransplantation assays were performed.
NSG mice were sublethally irradiated and transplanted with
GPI-80+ or GPI-80 HSPCs (respective populations from
50,000 CD34+ cells) (Figure 2C). Mice were bled retro-orbitally
at 6 weeks and 12–16 weeks to track peripheral blood reconsti-
tution, and hematopoietic organs were assessed for human
engraftment at 16 weeks. Robust populations of human CD45+
cells were detected in peripheral blood of all mice transplanted
with GPI-80+ HSPCs. The average human CD45+ bone marrow
chimerism of GPI-80+ transplants after 16 weeks was 46.4% ±
22.1% of total cells, CD13+ or CD66+ myeloid cells constituted
11.2% ± 9.4%, CD19+ B cells 17.7% ± 16.4%, and CD3+
T cells 5.6% ± 12.4% (Table S2). In contrast, GPI-80 HSPC
transplants did not yield detectable engrafted cells (0.2% ±
0.2%). Transplantation of CFSE-labeled HSPCs showed that
both GPI-80+ and GPI-80 HSPCs could be found in the BM
shortly after transplantation, implying defective engraftment/
self-renewal rather than lack of BM homing as the key difference
between GPI-80+ and GPI-80HSPCs (Figure 2D). These results
Figure 2. GPI-80 ExpressionDefinesHSPCs
with Self-Renewal and Engraftment Ability
(A) In vitro self-renewal/expansion assay of GPI-
80+ and GPI-80 HSPCs cocultured on OP9M2
stroma and analyzed at 2 and 4 weeks for the
presence of undifferentiated HSPCs. Growth of
total cells and expansion of CD34+CD38lo/CD90+
HSPCs onOP9M2 are shown (n = 3 different donor
tissues, which are representative examples of 10
independent experiments that showed the same
result). Flow cytometry plots of hematopoietic
populations after 2 and 4 weeks of coculture on
OP9M2 stroma are shown. Error bars represent
mean ± SD.
(B) Cell cycle analysis of FACS sorted FL HSPCs
cultured on OP9M2 overnight and pulsed with
BRDU (n = 3 different donor tissues analyzed in
two independent experiments). Representative
flow cytometry plots assessing BRDU incorpora-
tion in GPI-80+ and GPI-80 cells are shown. Error
bars represent mean ± SEM.
(C) Scheme of transplant assay for analysis of
engraftment ability of GPI-80+ and GPI-80
HSPCs. Each mouse was transplanted with a
sorted HSPC subset originating from 50,000
CD34+ cells. Flow cytometry analysis of human
hematopoietic engraftment in peripheral blood,
spleen, and BM of mice transplanted with GPI-80+
andGPI-80HSPCs from human FL is shown (p%
0.01) (n = 3 donor tissues assessed in three inde-
pendent experiments).
(D) Scheme of transplant assay for CFSE-labeled
HSPCs. Flow cytometry analysis of murine BM
16 hr posttransplant is shown (n = 3 donor tissues
assessed in two independent experiments). See
also Figure S2 and Table S2.
Cell Stem Cell
GPI-80 Marks Human Fetal HSCsindicate that only the GPI-80+ subset of human FL HSPCs
displays capacity for in vivo engraftment and multilineage he-
matopoietic reconstitution.
GPI-80Can BeUsed to Track Immunophenotypic HSPCs
with High Proliferative Potential through Early Human
Development
We next assessed whether GPI-80 expression marks undifferen-
tiated HSPC also in fetal BM (FBM), which is colonized after the
FL. FACS analysis demonstrated the presence of GPI-80+
HSPCs in FBM by 15 weeks of development. In vitro expansion
assays revealed that only GPI-80 HSPCs harbored in vitro
expansion ability in FBM, whereas GPI-80 HPSCs were not
sustained in culture (Figure 3A). Flow cytometry analysis showed
that some of the GPI-80+ HSPCs obtained from total BM
coexpress myeloid differentiation markers; however, Ficoll puri-
fication of FBM largely depleted hematopoietic cells that coex-Cell Stem Cell 16, 80–pressed myeloid and HSPC markers
and enriched for the undifferentiated
GPI-80+ HSPCs (Figure S3A).
We then assessed GPI-80 expression
in first trimester hematopoietic tissues.
FACS analysis of 10 week FL showed
the presence of GPI-80+ immunopheno-
typic HSPCs (Figure 3B). Analysis ofin vitro expansion ability of immunophenotypic HSPCs sorted
based on GPI-80 confirmed that, similar to the second trimester
FL and BM, in vitro self-renewal capacity in 10 week FL was
restricted to GPI-80+ cells (Figure S3A). In contrast, 8–10 week
FBM showed the absence of a robust population of undifferenti-
ated GPI-80+ HSPCs, although some GPI-80 expression was
observed in more differentiated cells that coexpressed lineage
markers (data not shown). Moreover, there was no expansion
of CD34+ cells from first trimester FBM in culture (data not
shown), consistent with the finding that in vitro expansion poten-
tial is restricted to GPI-80+ HSPCs.
To determine whether GPI-80 is expressed at a site of
HSPC emergence, we analyzed first trimester human pla-
centas. The first GPI-80+ immunophenotypic HSPC appeared
in the placenta between 4 and 5 weeks of development; by
5 weeks, a distinct population of GPI-80+ HSPCs was reproduc-
ibly observed (Figure 3C). Coinciding with the presence of a87, January 8, 2015 ª2015 Elsevier Inc. 83
Figure 3. GPI-80 Tracks Self-Renewing
HSPCs during Human Development
(A) Flow cytometry plot of 15 week fetal BM with
CD34, CD38, CD90, and GPI-80. Representative
FACS plots and growth curves of cultured GPI-80+
and GPI-80 HSPCs from fetal BM are shown (n =
3 independent experiments with different donor
tissues). Error bars represent mean ± SD.
(B) Representative flow cytometry plots of 10week
human FL with CD34, CD38, CD90, and GPI-80.
Representative FACS plots and growth curves of
cultured GPI-80+ and GPI-80 HSPCs from
10 week FL are shown (n = 3 independent exper-
iments with different donor tissues). Error bars
represent mean ± SD.
(C) Representative flow cytometry plots of 4 and
5 week placenta stained with CD34, CD38, CD90,
and GPI-80. Representative flow cytometry plots
of CD34+ placental cells after 2 weeks in culture on
OP9M2 are shown.
(D) Model of timeline of migration of GPI-80+
HSPCs in first and second trimester human he-
matopoietic tissues. See also Figure S3.
Cell Stem Cell
GPI-80 Marks Human Fetal HSCsGPI-80+ immunophenotypic HSPC, cultured CD34+ cells from
5 week placenta maintained undifferentiated HSPCs, many of
which coexpressed GPI-80 (Figure 3C).
Costaining for GPI-80 and endothelial and hematopoietic
markers indicated that in the placenta, similar to FL and FBM,
GPI-80+ cells were largely confined to the hematopoietic popu-
lation that expressed CD45 and lacked high VE-Cadherin and
CD31/PECAM expression (Figure S3C). Thus, unlike many
HSC markers, GPI-80 expression can distinguish HSPCs from
endothelium.
In summary, analysis of fetal hematopoietic tissues during
early human development indicates that in all niches studied,
GPI-80 expression correlates with the acquisition of HSPC
high proliferative potential and can be used to track the migra-
tion of candidate HSCs from the placenta to FL during first84 Cell Stem Cell 16, 80–87, January 8, 2015 ª2015 Elsevier Inc.trimester and to FBM by the beginning
of the second trimester (Figure 3D).
GPI-80 and ITGAM Are Critical for
Human Fetal HSPC Expansion
To provide insights into the mechanisms
of how human fetal HSCs sustain self-
renewal, we performed Affymetrix micro-
array analysis to identify genetic net-
works enriched in GPI-80+ HSPCs as
compared to their immediate progeny.
Q-Q probability plot revealed remark-
able similarity between GPI-80+ and
GPI-80 HSPCs (Figure 4A), in contrast
to the more obvious differences between
CD90+ HSPCs and downstream HPCs
(Figure 1B). Similar expression levels
of transcription factors governing
HSC specification (TAL1/SCL, LMO2,
RUNX1/AML, and MYB) and mainte-
nance (MLL1, MYC, SMAD4, HOXB4,HOXA9, BMI1, GFI1, and ETV6/TEL Figure 4B) or lineage
commitment (PU.1,BCL11A,CEPBA,GATA1, and IKAROS, Fig-
ure 4C) was observed, indicating that GPI-80 HSPCs have not
yet committed to specific downstream fates. Only 574 genes
were upregulated on GPI-80+ HSPCs while 246 genes were
downregulated (>2-fold, p < 0.05; Table S3). Of the 20 most
differentially expressed annotated genes, three were transcrip-
tion factors (HIF3a, TOB1, and KLF4) with no known function in
HSCs.
The second most highly upregulated transcript was Integrin
a-M (ITGAM, or CD11b) (Figure 4D), an a integrin component
of the MAC-1 (CR3) complex that consists of ITGAM and
ITGB2 (or CD18). ITGAM colocalizes with GPI-80 on neutro-
phils, enabling their adherence and extravasation (Huang
et al., 2004). Flow cytometry of FL and placental HSPCs
Figure 4. GPI-80 and ITGAM Are Required
for Maintaining Undifferentiated HSPCs
(A) Quantile-Quantile plot comparing differentially
expressed genes between GPI-80+ and GPI-80
HSPCs.
(B) Bar graphs showing the relative expression of
known transcription factors required for HSC
development or maintenance.
(C) Bar graphs showing the relative expression of
transcription factors responsible for lineage dif-
ferentiation.
(D) Heat map illustrating the top 20 annotated
genes significantly and consistently upregulated
among replicates (n = 3 fetal livers, p < 0.05) in
GPI-80+ HSPCs.
(E) Representative 15 week FL and 5 week
placental tissue stained for CD34, CD38, CD90,
GPI-80, and ITGAM.
(F) Representative ImageStream images of
15 week CD34+ FL cells stained for CD90, GPI-80,
and ITGAM.
(G) Representative flow cytometry plots of
cultured CD34+ FL cells after lentiviral knockdown
of GPI-80 or ITGAM. Quantifications of expansion
of total cells and HSPC population after knock-
down of GPI-80 or ITGAM with two different
shRNA vectors are shown (n = 3 donor tissues
analyzed in two independent experiments). Error
bars represent mean ± SD.
(H) Representative flow cytometry plots of mouse
BM 10 weeks after transplantation with human FL
CD34+ cells transduced with control LKO vector,
shGPI-80 vector, or shITGAM vector. Quantifica-
tion of engrafted cells in blood and BM is shown
(n = 3 donor tissues analyzed in two independent
experiments). See also Figure S4, Table S3, and
Table S4.
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GPI-80 Marks Human Fetal HSCsdemonstrated robust coexpression of ITGAM and ITGB2 on
GPI-80+ HSPCs (Figure 4E, Figure S4A). ImageStream analysis
was used to localize ITGAM relative to GPI-80 on HSPC sur-
faces. Distinct regions of colocalization between GPI-80 and
ITGAM were visualized, as described on neutrophils (Huang
et al., 2004), while there was limited colocalization between
GPI-80 and CD90, another GPI-anchored surface protein (Fig-
ure 4F). These data suggested that GPI-80 and ITGAM function
together in HSCs.
To assess whether GPI-80 and/or ITGAM are required for
maintaining HSC properties, we performed lentiviral-mediated
shRNA knockdown of GPI-80 and ITGAM on FL CD34+ cells.
FACS analysis confirmed a reduction of GPI-80 and ITGAM in
HSPCs by 1 week in culture with two independent shRNAs (Fig-
ure S4B). Knockdown of either protein led to progressive deple-
tion of undifferentiated HSPCs on OP9M2 stroma (Figure 4G) butCell Stem Cell 16, 80–did not impair their ability to differentiate
into myeloid, erythroid, or lymphoid cells
(Figure S4C). Moreover, transplantation
of shRNA-transduced HSPCs into
NSG mice showed that loss of GPI-80
or ITGAM severely compromised their
engraftment/reconstitution ability in vivo
(Figure 4H, Table S4). Collectively, thesedata suggest that GPI-80 and ITGAM are not only markers for
the highly self-renewing fetal HSCs but also required for their
proper function.
DISCUSSION
Uncovering the identity and regulation of the self-renewing HSCs
as they emerge and expand during embryogenesis is of para-
mount significance, both for understanding the fundamental
mechanisms governing ‘‘stemness’’ and for bringing PSC deriv-
atives to clinical applications. We identified GPI-80 as a surface
protein that demarcates HSCs from non-self-renewing progeni-
tors during human development. Although the GPI-80 subset of
FL HSPCs also displays a surface immuophenotype associated
with human HSCs (e.g., CD34+CD38lo/CD90+) and exhibits
striking similarity with GPI-80+ HSPCs in global gene expression,87, January 8, 2015 ª2015 Elsevier Inc. 85
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GPI-80 Marks Human Fetal HSCsthey are profoundly different functionally in lacking the ability to
self-renew and engraft.
Analysis of GPI-80 expression at different stages and anatom-
ical sites during human development revealed a correlation of
GPI-80 expression with the capacity to expand undifferentiated
HSPCs in MSC stroma and engraft in vivo. Thus, GPI-80 expres-
sion provides a unique tool for temporal and spatial tracking of
candidate HSPCs with high proliferative potential as they
migrate between fetal hematopoietic organs. GPI-80+ HSPCs
appear in the human placenta by 5weeks of development, which
parallels the timewhen transplantable HSCs populate themouse
placenta (E11.5) (Gekas et al., 2005). In human placentas, trans-
plantable HSCs have been detected as early as 6 weeks of hu-
man development (Robin et al., 2009), although another study
did not detect robust reconstitution of placental cells until the
second trimester, while AGM cells from first trimester tissues en-
grafted readily (Ivanovs et al., 2011). Due to the techniques used
for the elective terminations to obtain tissues, it was not possible
to obtain intact embryos to analyze GPI-80 expression in human
AGM. Future studies will be needed to investigate whether GPI-
80 is already expressed by the AGMHSPCs as they emerge from
hemogenic endothelium, or only after HSPCs have migrated to
the placenta and FL. In contrast to CD34 and CD90, which,
similar to many HSC markers, are also expressed in endothe-
lium, GPI-80 expression was not observed in VE-Cadherinhigh
endothelial cells, but only after HSPCs coexpressed the panhe-
matopoietic marker CD45. Our studies also show that GPI-80 is
not expressed in hemogenic endothelial precursors isolated
from embryoid bodies during human ESC differentiation; how-
ever, GPI-80 can be induced in a subset of CD34+CD38CD90+
CD45+ cells during their developmental maturation on OP9M2
stroma, further suggesting that GPI-80 expression is turned
on after departure from hemogenic endothelium (D.R. Dou and
H.K.A.M., data not shown). The finding that GPI-80 expression
can be detected in PSC-derived HPCs that are defective in
self-renewal implies that GPI-80 expression is necessary, but
not sufficient, for self-renewal ability. Nevertheless, GPI-80
now represents an attractive candidate to track the appearance
and developmental maturation of PSC-derived HSC precursors.
An intriguing property of GPI-80 compared to many known
HSC surface markers is that it is functionally required for HSC
self-renewal; this observation opens new avenues to understand
HSC self-renewal mechanisms during human development.
Although GPI-80 does not possess an intracellular domain to
convey a signal from the niche, it associates with the MAC-1 in-
tegrin complex that consists of ITGAM and ITGB2, which in leu-
kocytes cooperate with GPI-80 to mediate their migration and
extravasation (Huang et al., 2004). Mac1 is also expressed on
mouse fetal hematopoietic stem cells (Morrison et al., 1995b)
and downregulated in adult BM HSCs (Morrison and Weissman,
1994). Our finding that GPI-80 and ITGAM colocalize on highly
self-renewing human fetal HSPCs, and that disruption of the
expression of either leads to loss of undifferentiated HSPCs in
culture and prevents engraftment in vivo, suggests that they
function together to protect HSCs. These findings introduce
the unanticipated concept that HSCs, the most undifferentiated
cells in hematopoietic hierarchy, utilize mechanisms employed
by terminally differentiated leukocytes during immune response
for maintaining ‘‘stemness.’’86 Cell Stem Cell 16, 80–87, January 8, 2015 ª2015 Elsevier Inc.In stark contrast to the profound functional differences be-
tween GPI-80+ and GPI-80 HSPCs, gene expression profiling
showed striking molecular similarity, including fundamental he-
matopoietic programs known to govern HSC specification and
function. Nevertheless, our analysis uncovered unique differen-
tially expressed genes that are candidates for governing HSC
self-renewal. HIF3-a, a transcription factor whose expression
declines during culture (Magnusson et al., 2013) when HSPCs
begin to lose their functional properties, was the most differen-
tially expressed gene between GPI-80+ and GPI-80 HSPCs.
We believe that deciphering the function of genes upregulated
in highly self-renewing GPI-80+ fetal HSCs will provide an invalu-
able resource for dissecting the genetic programs that govern
‘‘stemness’’ in HSCs. Inducing these programs in human ESC
and iPSC-derived HPCs may bring us closer to creating self-re-
newing HSCs in vitro for clinical applications.
EXPERIMENTAL PROCEDURES
Ethical Statement
Experimental protocols involving mice were reviewed and approved by the
UCLA Animal Research Committee (Protocol number 2005-109). Fetal he-
matopoietic tissues were either discarded material devoid of personal identi-
fiers obtained from elective terminations performed by UCLA Medical Center
or purchased from Novogenix. All material was used with written informed
consent.
Tissues, Cell Culture, and Hematopoietic Assays
In vitro HSPC expansion was assayed on OP9M2 stroma and B and T cell as-
says were performed on OP9M2 and OP9DL1, respectively, as described in
Magnusson et al. (2013) and the Supplemental Information. Processing and
transplantation of hematopoietic tissues are described in the Supplemental
Experimental Procedures.
Lentiviral shRNA Knockdown
pLKO lentiviral vectors from the TRC library (Sigma) were produced and
transduced in FL CD34+ cells as described in the Supplemental Information.
Two different shRNAs with confirmed knockdown of GPI-80 or ITGAM
were used: TRCN0000158666 (GPI-80 1), TRCN0000161721 (GPI-80 2),
TRCN0000029051 (ITGAM 1), and TRCN0000029050 (ITGAM 2).
Graphical and Statistical Analysis
Graphs were generated and statistics were analyzed using GraphPad Prism
software. Student’s two-tailed t tests were used to calculate p values.
Gene Expression, Flow Cytometry Analysis, and Image Stream
See the Supplemental Information.
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